Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
NAD+: Evidence Summary
Evidence summary for NAD+ across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to NAD+ overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Cellular aging | Tier B | 8 | Growing human trial evidence for NMN/NR supplementation |
| Energy metabolism | Tier B | 6 | Consistent improvements in mitochondrial function markers |
| Neuroprotection | Tier C | 5 | Preclinical data strong, human data emerging |
References (5)
- Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure. . Nature cancer (2025) PMID: 40394194
- Phages reconstitute NAD . Nature (2024) PMID: 39322677
- LXR/CD38 activation drives cholesterol-induced macrophage senescence and neurodegeneration via NAD . Cell reports (2024) PMID: 38636518
- Nicotinamide Mononucleotide Supplementation Improves Mitochondrial Dysfunction and Rescues Cellular Senescence by NAD . International journal of molecular sciences (2022) PMID: 36499074
- Macrophage de novo NAD . Nature immunology (2019) PMID: 30478397